Skip to content
    Guidelines & Consensus

    Implementing the 2026 AUA/SUO Guideline for Metastatic Castration-Resistant Prostate Cancer

    Fred SaadThe Journal of Urology

    Implementing the 2026 AUA/SUO Guideline for Metastatic Castration-Resistant Prostate Cancer
    The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) address clinical implementation strategies for the 2026 clinical practice guideline on metastatic castration-resistant prostate cancer (mCRPC). Published in The Journal of Urology, this guidance reviews key updates, practice changes necessary for clinicians treating advanced prostate cancer, and future directions in mCRPC management.

    Key Takeaways

    • The 2026 AUA/SUO guideline establishes updated recommendations and implementation strategies for the clinical management of metastatic castration-resistant prostate cancer.
    Read the original sourceThe Journal of Urology